Plain-English translation of NCT03978078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are building a database of blood samples and clinical information from patients with metastatic digestive cancers (cancers that have spread) who are receiving first or second-line treatment. The goal is to find new biomarkers—measurable signals in the blood—that can help doctors predict which patients will respond well to treatment and catch resistance early, without needing painful biopsies.
Currently, doctors have very few blood-based tools to predict how well a patient will respond to cancer treatment, and the tests that do exist often require invasive biopsies. This study aims to discover new blood markers that can be checked repeatedly and non-invasively to personalize treatment decisions and monitor how your cancer is responding over time.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken before you start treatment, then every other month during your treatment, continuing through the end of your therapy. These blood draws are minimally invasive and happen alongside your regular cancer care visits. Researchers will also record your clinical information (treatment type, response, side effects) in a database to help identify patterns that predict treatment success.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment target
~200 participants
Started
September 2016
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aurore MOUSSION
Institut régional du cancer de Montpellier
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.